Literature DB >> 469022

Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.

J O Covinsky, J Russo, K L Kelly, J Cashman, E N Amick, W D Mason.   

Abstract

A comparison of the bioavailability of quinidine sulfate to quinidine gluconate tablets in a single-dose randomized cross-over design with 20 healthy volunteers shows that the sulfate salt is more rapidly absorbed and provides significantly greater peak concentrations 1 hour after administration as compared to the peak levels achieved with the gluconate salt at approximately 5 hours after administration. When adjusted for the actual amount of quinidine contained in each tablet, there was no significant difference in the amount of quinidine bioavailable. Since quinidine gluconate absorption is significantly slower than quinidine sulfate, a combination of the two dosage forms may be utilized in providing the loading dose. Based on the computer modeling and the clinical data accumulated by this laboratory (unpublished) over the past four years, quinidine gluconate, in the dosage form utilized in this study, provides more constant blood levels with smaller differences between the Cpmax and Cpmin than the sulfate when administered every 6 or 8 hours. Further controlled clinical studies are needed to confirm these observations in patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 469022     DOI: 10.1002/j.1552-4604.1979.tb02479.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  The second peak in the serum levels curve after oral administration of a slow-release quinidine dosage form: effect of food.

Authors:  J Spénard; G Sirois; M A Gagnon
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 2.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Comparative bioavailability study of three sustained release quinidine formulations.

Authors:  W A Mahon; J S Leeder; M M Brill-Edwards; J Correia; S M MacLeod
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 5.  Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts.

Authors:  Sonali S Bharate
Journal:  Pharm Res       Date:  2021-07-23       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.